HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Erdely, A. Articles by Baylis, C. Search for Related Content PubMed PubMed Citation Articles by Erdely, A. Articles by Baylis, C.

CALL FOR PAPERS
Cardiovascular-Kidney Interactions in Health and Disease

Resistance to renal damage by chronic nitric oxide synthase inhibition in the Wistar-Furth rat

¹Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, Pennsylvania; ²Department of Nutrition, West Virginia University, Morgantown, West Virginia; and ³Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida

Submitted 23 June 2005 ; accepted in final form 25 August 2005

Chronic nitric oxide synthase inhibition (NOSI) causes chronic kidney disease (CKD) in the Sprague Dawley (SD) rat. We previously showed that the Wistar-Furth (WF) rats are resistant to several models of CKD and maintain renal nitric oxide (NO) production compared with SD rats, whereas low-dose NOSI caused progression of CKD in WF rats. Here, we evaluate the impact of high-dose chronic NOSI in WF and SD rats, as well as intrarenal responses to an acute pressor dose of NOSI in the normal WF. Rats were given N^G-nitro-L-arginine methyl ester (L-NAME) (150 and 300 mg/l for 6–10 wk) in the drinking water after an initial bolus tail vein injection. Both strains showed significant reductions in total NO production with chronic L-NAME. SD given 150 mg/l L-NAME for 6 wk developed proteinuria and renal injury, whereas WF rats receiving 150 mg/l L-NAME for 6–10 wk or 300 mg/l for 6 wk developed no proteinuria and minimal renal injury. Blood pressure was significantly elevated with chronic NOSI in both strains but was higher in the SD rat. There was little impact on renal nitric oxide synthase expression with L-NAME, except that cortical endothelial nitric oxide synthase abundance increased in WF after 6 wk (150 mg/l). Micropuncture experiments with acute pressor NOSI resulted in similar increases in systemic blood pressure in SD and WF rats, whereas WF rats showed a much smaller increment in glomerular blood pressure compared with SD rats. In conclusion, WF rats do not develop renal injury after chronic NOSI at, or above, a dose that causes significant injury in the SD rat. This protection may be associated with protection from glomerular hypertension.

proteinuria; glomerular sclerosis; creatinine clearance; Sprague- Dawley

This article has been cited by other articles:

				C. Baylis Nitric oxide deficiency in chronic kidney disease Am J Physiol Renal Physiol, January 1, 2008; 294(1): F1 - F9. [Abstract] [Full Text] [PDF]

				A. Erdely, G. Freshour, Y.-L. Tain, K. Engels, and C. Baylis DOCA/NaCl-induced chronic kidney disease: a comparison of renal nitric oxide production in resistant and susceptible rat strains Am J Physiol Renal Physiol, January 1, 2007; 292(1): F192 - F196. [Abstract] [Full Text] [PDF]

				C. S. Wilcox Special feature: cardiovascular-kidney interactions in health and disease Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R34 - R36. [Full Text] [PDF]